Select Page

Abstract Number: 487 – Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Presenter: Luca Bertamini, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical PracticeDate & Time: Sunday, December 8, 2024 9:30 AM–9:45 AMLocation: Pacific Ballroom...

Abstract Number: 362 – Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Presenter: Sonja Zweegman, MD, PhDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment DecisionsDate & Time: Saturday, December 7, 2024 4:15 PM–4:30 PMLocation: San...